Recent Updates
Recently added Catalysts
CTMX

CytomX Therapeutics to Announce Third Quarter 2017 Financial Results

Thursday, October 26, 2017 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: SOUTH SAN FRANCISCO, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will announce financial results for the third quarter ended September

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
6.8%
average across 7 past catalysts
Cash runway
~54 mo
Minimal dilution risk
Lead asset
CX-2009
Phase 2 · Neoplasms

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., Oct. 26, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will announce financial results for the third quarter ended September 30, 2017, on November 7, 2017, after the NASDAQ market closing.
The company will not conduct a conference call in conjunction with this financial results press release.
About CytomX Therapeutics
ShareAdd on Google
Tags: CTMX Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Oct 26, 2017

Biotech snapshot

Cash runway
$330M liquidity · $6M/mo burn
~54 mo
Minimal dilution risk
Lead asset
CX-2009Phase 2
Neoplasms →

Catalyst track record

+53%
best trade around CTMX's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for CTMX.

See every catalyst's timing & PoA →